- Home
- LAB vs UPB Comparison
LAB vs UPB Comparison
Compare LAB & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- UPB
- Stock Information
- Founded
- LAB 1999
- UPB 2021
- Country
- LAB United States
- UPB United States
- Employees
- LAB N/A
- UPB N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- UPB
- Sector
- LAB Industrials
- UPB
- Exchange
- LAB Nasdaq
- UPB NYSE
- Market Cap
- LAB 435.8M
- UPB 417.2M
- IPO Year
- LAB 2011
- UPB 2024
- Fundamental
- Price
- LAB $1.24
- UPB $8.81
- Analyst Decision
- LAB Buy
- UPB Strong Buy
- Analyst Count
- LAB 2
- UPB 4
- Target Price
- LAB $2.50
- UPB $56.50
- AVG Volume (30 Days)
- LAB 1.2M
- UPB 310.2K
- Earning Date
- LAB 05-06-2025
- UPB 05-14-2025
- Dividend Yield
- LAB N/A
- UPB N/A
- EPS Growth
- LAB N/A
- UPB N/A
- EPS
- LAB N/A
- UPB N/A
- Revenue
- LAB $174,432,000.00
- UPB $2,370,000.00
- Revenue This Year
- LAB N/A
- UPB N/A
- Revenue Next Year
- LAB $12.77
- UPB $0.99
- P/E Ratio
- LAB N/A
- UPB N/A
- Revenue Growth
- LAB 64.03
- UPB N/A
- 52 Week Low
- LAB $0.97
- UPB $5.14
- 52 Week High
- LAB $2.74
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- LAB 56.32
- UPB N/A
- Support Level
- LAB $0.99
- UPB N/A
- Resistance Level
- LAB $1.18
- UPB N/A
- Average True Range (ATR)
- LAB 0.09
- UPB 0.00
- MACD
- LAB 0.02
- UPB 0.00
- Stochastic Oscillator
- LAB 75.00
- UPB 0.00
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.